卖什么
无创神经调控
商业模式拆解
买家：谁掌握预算？
未核实Hospital ICU and neurocritical care leadership / value-analysis committees (ICU cost burden is the stated pitch).
触发点：什么让他们现在购买？
ICU cost burden of $254B (1% of US GDP); inflammation drives complications and excess costs, with high-cost patients being 10% of patients and consuming 50% of resources.
经济账：省了什么，怎么收费？
Medical device to be sold to hospitals on outcome and cost-of-care value; claims randomized pilot studies showed improved outcomes, shorter length of stay and lower cost (results unpublished); pre-commercial.
渠道：怎么接触到客户？
未核实Pre-commercial clinical-stage; direct hospital sales expected after regulatory clearance.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-07-28 | 种子轮 | $5.7M | — | news.google.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.